FIRST AMENDMENT TO REVENUE INTEREST PURCHASE AND SALE AGREEMENTRevenue Interest Purchase and Sale Agreement • August 9th, 2024 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
This First Amendment to Revenue Interest Purchase and Sale Agreement (this “Amendment”) is made as of May 24, 2024, by and among DERMAVANT SCIENCES GMBH, a limited liability company organized under the laws of Switzerland (“Dermavant”), DERMAVANT SCIENCES, LTD., an exempted company organized under the laws of Bermuda, solely for purposes of Section 5.21 and Article VIII of the RIPSA (“Parent” and, together with Dermavant, the “Dermavant Parties”), XYQ LUXCO S.À R.L. (“XYQ Luxco”), NovaQuest Co-Investment Fund XVII, L.P. (“NovaQuest”), MAM Tapir Lender, LLC (“Marathon” and, with XYQ Luxco and NovaQuest, the “Purchasers”) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as collateral agent on behalf of the Purchasers (the “Collateral Agent”).
Revenue Interest Purchase and Sale Agreement dated as of May 14, 2021 by and among Dermavant Sciences GmbH, the Purchasers party hereto, and solely for purposes of Article IX hereof, U.S. Bank National Association, as collateral agent on behalf of the...Revenue Interest Purchase and Sale Agreement • July 1st, 2021 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
This Revenue Interest Purchase and Sale Agreement (this “Agreement”) is entered into as of May 14, 2021 (the “Effective Date”) by and among Dermavant Sciences GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) organized under the laws of Switzerland (“Dermavant”), and, severally and not jointly, the other entities named on the signature pages hereto (together with such entities’ successors and assigns, collectively, the “Purchasers” and, each, a “Purchaser”) and, solely for purposes of Article IX, U.S. Bank National Association, as collateral agent on behalf of the Purchasers (the “Collateral Agent”). Each of the Purchasers and Dermavant is referred to herein individually as a “Party” and collectively as the “Parties”.
Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. Execution Version...Revenue Interest Purchase and Sale Agreement • August 8th, 2024 • Verona Pharma PLC • Pharmaceutical preparations • New York
Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. Execution Version...Revenue Interest Purchase and Sale Agreement • May 10th, 2024 • Verona Pharma PLC • Pharmaceutical preparations • New York
